Kanat, MustafaDeFronzo, RalphAbdul-Ghani, Muhammad10.07.20192019-07-1010.07.20192019-07-102015Kanat, M., DeFronzo, R. ve Abdul-Ghani, M. (2015). Treatment of prediabetes. World Journal of Diabetes, 6(12), 1207-1222. https://dx.doi.org/10.4239/wjd.v6.i12.12071948-9358https://dx.doi.org/10.4239/wjd.v6.i12.1207https://hdl.handle.net/20.500.12511/4082WOS: 000362084500001PubMed ID: 26464759Progression of normal glucose tolerance (NGT) to overt diabetes is mediated by a transition state called impaired glucose tolerance (IGT). Beta cell dysfunction and insulin resistance are the main defects in type 2 diabetes mellitus (type 2 DM) and even normoglycemic IGT patients manifest these defects. Beta cell dysfunction and insulin resistance also contribute to the progression of IGT to type 2 DM. Improving insulin sensitivity and/or preserving functions of beta-cells can be a rational way to normalize the GT and to control transition of IGT to type 2 DM. Loosing weight, for example, improves whole body insulin sensitivity and preserves beta-cell function and its inhibitory effect on progression of IGT to type 2 DM had been proven. But interventions aiming weight loss usually not applicable in real life. Pharmacotherapy is another option to gain better insulin sensitivity and to maintain beta-cell function. In this review, two potential treatment options (lifestyle modification and pharmacologic agents) that limits the IGT-type 2 DM conversion in prediabetic subjects are discussed.enAttribution-NonCommercial 4.0 Internationalinfo:eu-repo/semantics/openAccessPrediabetesImpaired Fasting GlucoseImpared Glucose ToleranceDiabetes PreventionType 2 Diabetes MellitusReview Article6121207122210.4239/wjd.v6.i12.1207Q3